Suresh S. Ramalingam

Nov 29, 2024 | nature.com | Fei Zhou |Xiuning Le |Suresh S. Ramalingam

AbstractThe discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has revolutionized the treatment paradigm for patients with non-small-cell lung cancer (NSCLC). Currently, third-generation EGFR TKIs, which are often characterized by potent central nervous system penetrance, are the standard-of-care first-line treatment for advanced-stage EGFR-mutant NSCLC.

Sep 24, 2024 | targetedonc.com | Suresh S. Ramalingam

Suresh S. Ramalingam, MD, FACP, FASCO, executive director of the Winship Cancer Institute of Emory University, discusses the background and next steps of the LAURA study (NCT03521154) which evaluated osimertinib (Tagrisso) for the treatment of patients with unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutations.

Aug 19, 2024 | nature.com | Suresh S. Ramalingam

In the past 2 years, substantial improvements have been made in the management of advanced-stage EGFR-mutant non-small-cell lung cancer. Recent studies have suggested added benefit from the combination of third-generation tyrosine-kinase inhibitors with either chemotherapy or a bispecific antibody targeting EGFR and MET. Herein, we summarize these advances and their implications for clinical practice.

Jun 27, 2024 | onclive.com | Suresh S. Ramalingam

CommentaryVideoJune 27, 2024Author(s):Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting. Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C.

Jun 24, 2024 | onclive.com | Suresh S. Ramalingam

Osimertinib (osi) After Definitive Chemoradiotherapy (CRT) in Patients (pts) With Unresectable Stage (stg) III Epidermal Growth Factor Receptor-Mutated (EGFRm) NSCLC: Primary Results of the Phase 3 LAURA StudyThe LAURA study (NCT03521154) evaluates the efficacy and safety of Osimertinib as a maintenance therapy following chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer.